Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Share on StockTwits

Kiniksa Pharmaceuticals (NASDAQ:KNSA) posted its quarterly earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.03, Fidelity Earnings reports.

Shares of KNSA stock opened at $11.10 on Wednesday. The business has a 50 day moving average of $13.07. Kiniksa Pharmaceuticals has a one year low of $10.70 and a one year high of $32.88. The firm has a market cap of $621.95 million, a price-to-earnings ratio of -3.18 and a beta of -1.56.

Several analysts have recently weighed in on KNSA shares. JMP Securities dropped their price target on shares of Kiniksa Pharmaceuticals to $35.00 and set an “outperform” rating for the company in a research note on Wednesday. They noted that the move was a valuation call. Zacks Investment Research raised shares of Kiniksa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 4th. Wedbush reissued a “buy” rating on shares of Kiniksa Pharmaceuticals in a research note on Wednesday. Finally, ValuEngine raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $29.25.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Article: Understanding the two types of arbitrage

Earnings History for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

-$0.61 Earnings Per Share Expected for Titan Medical Inc.  This Quarter
-$0.61 Earnings Per Share Expected for Titan Medical Inc. This Quarter
Zacks: Analysts Expect TC Pipelines, LP  to Post $0.63 Earnings Per Share
Zacks: Analysts Expect TC Pipelines, LP to Post $0.63 Earnings Per Share
Zacks: Brokerages Expect Hyatt Hotels Co.  to Announce $0.27 EPS
Zacks: Brokerages Expect Hyatt Hotels Co. to Announce $0.27 EPS
Analysts Expect Hyatt Hotels Co.  Will Announce Quarterly Sales of $1.18 Billion
Analysts Expect Hyatt Hotels Co. Will Announce Quarterly Sales of $1.18 Billion
$0.16 Earnings Per Share Expected for Liberty Global PLC  This Quarter
$0.16 Earnings Per Share Expected for Liberty Global PLC This Quarter
Zacks: Brokerages Anticipate CryoPort Inc  to Post -$0.07 EPS
Zacks: Brokerages Anticipate CryoPort Inc to Post -$0.07 EPS


© 2006-2019 Ticker Report